title: Pituitary function in thalassemic patients and the effect of chelation therapy.
abstract: This study examined anterior pituitary function and the effect of chelation therapy in 31 patients with beta-thalassemia/HbE disease. Patients were divided into those receiving chelation therapy by deferoxamine and those receiving no such therapy (control group). Pituitary function studies were repeated in both groups 18 months later. The results showed decreased pituitary responses following stimulation in 22 patients. Among these, gonadotropin and PRL responses were most affected. After 18 months, serum ferritin levels had significantly decreased in the deferoxamine group. PRL and GH responses were improved in 3 patients receiving chelation therapy without changes in other hormone responses. In contrast, no changes in pituitary responses were shown in the control group at the end of follow-up. There were 6 drop-outs (4 in the control and 2 in the deferoxamine group) and 3 deaths (2 in the control and 1 in the deferoxamine group) during 18 months. In conclusion, gonadotropin and PRL deficiencies occur most frequently in thalassemic patients. Chelation therapy for 18 months markedly reduced serum ferritin level and might preserve or improve PRL and GH secretions, but seems to have no beneficial effects on other pituitary hormone reserves.
authors.affiliation: Department of Medicine, Siriraj Hospital, Bangkok, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Vannasaeng
authors.forename: S
authors.initials: S
authors.lastname: Fucharoen
authors.forename: P
authors.initials: P
authors.lastname: Pootrakul
authors.forename: S
authors.initials: S
authors.lastname: Ploybutr
authors.forename: P
authors.initials: P
authors.lastname: Yansukon
mesh_terms: D000328:Adult; D015913:Chelation Therapy; D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D005293:Ferritins; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007003:Hypoglycemia / Q000188:drug therapy; D007328:Insulin / Q000009:adverse effects; D007501:Iron; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D011388:Prolactin / Q000097:blood; D013789:Thalassemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013972:Thyrotropin / Q000097:blood
chemical_list: D006454:Hemoglobins; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013006:Growth Hormone; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine; D006854:Hydrocortisone